Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The post-2009 influenza pandemic era: time to revisit antibody immunodominance
Kristien Van Reeth
Kristien Van Reeth
Published October 8, 2018
Citation Information: J Clin Invest. 2018;128(11):4751-4754. https://doi.org/10.1172/JCI124151.
View: Text | PDF
Commentary

The post-2009 influenza pandemic era: time to revisit antibody immunodominance

  • Text
  • PDF
Abstract

The current inactivated influenza vaccines rely on the induction of neutralizing antibodies against the head domain of the viral hemagglutinin (HA). The HA head contains five immunodominant antigenic sites, all of which are subject to antigenic drift, thereby limiting vaccine efficacy. Bypassing the immune system’s tendency to focus on the most variable regions of the HA may be a step toward more broadly protective influenza vaccines. However, this requires a better understanding of the biological meaning of immunodominance, and of the hierarchy between different antigenic sites. In this issue of the JCI, Liu et al. determined the immunodominance of the five antigenic sites of the HA head in experimentally infected mice, guinea pigs, and ferrets. All three species exhibited different preferences for the five sites of the 2009 pandemic H1N1 strain. Moreover, human subjects exhibited yet a different pattern of immunodominance following immunization with the standard inactivated influenza vaccine. Together, these results have important implications for influenza vaccine design and interpretation of animal models.

Authors

Kristien Van Reeth

×

Figure 1

Schematic of influenza HA structure and variability.

Options: View larger image (or click on image) Download as PowerPoint
Schematic of influenza HA structure and variability.
(A) Schematic repre...
(A) Schematic representation of the structure of the H1N1 HA protein with its head and stalk domain. The HA head contains five immunodominant antigenic sites, designated Sa, Sb, Ca1, Ca2, and Cb. For the Sa and Sb sites, the S stands for strain-specific. These sites are most variable and are in close proximity to the receptor binding site. The C sites are cross-reactive sites that are less variable between H1N1 strains and are located further downward on the HA. (B) HA head epitopes that are outside the classical antigenic sites and, in particular, epitopes in the HA stalk are more conserved among different influenza A viruses. These sites are targeted to a much lower degree by antibody-producing B cells. (C) Influenza virus particle with HA and NA protruding from the surface. The combination of HA and NA proteins determines the subtype of the virus, such as H1N1, H5N1, etc.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts